Teacher Retirement System of Texas Purchases 6,742 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Teacher Retirement System of Texas grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,565 shares of the biopharmaceutical company's stock after buying an additional 6,742 shares during the period. Teacher Retirement System of Texas' holdings in TG Therapeutics were worth $1,311,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of TGTX. Arizona State Retirement System boosted its stake in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after acquiring an additional 364 shares during the last quarter. Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Brookstone Capital Management increased its holdings in shares of TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares in the last quarter. Daymark Wealth Partners LLC raised its position in shares of TG Therapeutics by 1.7% during the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in shares of TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after purchasing an additional 837 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

TG Therapeutics Stock Up 5.5 %

TGTX stock traded up $2.07 during midday trading on Wednesday, hitting $39.82. The company's stock had a trading volume of 4,483,390 shares, compared to its average volume of 3,078,007. The company's fifty day moving average price is $34.94 and its 200 day moving average price is $30.67. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $6.25 billion, a P/E ratio of -398.16 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.50% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.